Shield Therapeutics (LON:STX) Given “Buy” Rating at Peel Hunt

Peel Hunt restated their buy rating on shares of Shield Therapeutics (LON:STX) in a research report sent to investors on Wednesday morning, Marketbeat.com reports. They currently have a GBX 15 target price on the stock.

Shield Therapeutics Stock Performance

LON:STX opened at GBX 7.70 on Wednesday. The firm has a market capitalization of £80.21 million, a PE ratio of -385.00 and a beta of 1.42. The stock’s fifty day moving average is GBX 6.61 and its 200 day moving average is GBX 4.06. Shield Therapeutics has a fifty-two week low of GBX 2.10 and a fifty-two week high of GBX 9.10. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.